SI-BONE to Present at Truist Securities MedTech Conference on June 17, 2025
- SANTA CLARA, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming 2025 Truist Securities MedTech Conference in Boston, MA.
- 06/04/2025
|
SI-BONE to Truist Securities MedTech Conference on June 17, 2025
- SANTA CLARA, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming 2025 Truist Securities MedTech Conference in Boston, MA. Management will be hosting a fireside chat on Tuesday, June 17, 2025, at 10:00 a.m. Pacific Time/1:00 p.m. Eastern Time.
- 06/04/2025
|
SI-BONE to Present at Goldman Sachs 46th Global Healthcare Conference on June 10, 2025
- SANTA CLARA, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming 2025 Goldman Sachs 46th Global Healthcare Conference in Miami Beach, FL. Management will be hosting a fireside chat on Tuesday, June 10, 2025, at 8:20 a.m. Pacific Time/11:20 a.m. Eastern Time.
- 05/28/2025
|
Wall Street Analysts See a 34.22% Upside in Si-Bone (SIBN): Can the Stock Really Move This High?
- The average of price targets set by Wall Street analysts indicates a potential upside of 34.2% in Si-Bone (SIBN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 05/26/2025
|
4 Recent Earnings Winners Riding Fresh Momentum in May
- The market turbulence in 2025 has sent stocks zig-zagging up and down. Despite the unavoidable impact of political developments on share price performance, some companies have seen major gains based on a more traditional driver of motion: strong earnings reports.
- 05/14/2025
|
What Makes Si-Bone (SIBN) a Strong Momentum Stock: Buy Now?
- Does Si-Bone (SIBN) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 05/13/2025
|
Wall Street Analysts Think Si-Bone (SIBN) Could Surge 41.21%: Read This Before Placing a Bet
- The consensus price target hints at a 41.2% upside potential for Si-Bone (SIBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 05/08/2025
|
SI-BONE To Present at BofA Securities 2025 Healthcare Conference on May 13, 2025
- SANTA CLARA, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming 2025 BofA Securities Healthcare Conference in Las Vegas. Management will be hosting a fireside chat on Tuesday, May 13, 2025, at 8:40 a.m. Pacific Time/11:40 a.m. Eastern Time.
- 05/06/2025
|
SI-BONE, Inc. (SIBN) Q1 2025 Earnings Call Transcript
- SI-BONE, Inc. (NASDAQ:SIBN ) Q1 2025 Earnings Conference Call May 5, 2025 4:30 PM ET Company Participants Saqib Iqbal - VP, FP&A, Investor Relations Laura Francis - Chief Executive Officer Anshul Maheshwari - Chief Financial Officer Conference Call Participants Craig Bijou - Bank of America David Turkaly - Citizens JMP Young Li - Jefferies Caitlin Cronin - Canaccord Genuity David Saxon - Needham & Company Operator Good afternoon. And welcome to SI-BONE's First Quarter 2025 Earnings Conference Call.
- 05/05/2025
|
Si-Bone (SIBN) Reports Q1 Loss, Tops Revenue Estimates
- Si-Bone (SIBN) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.27 per share a year ago.
- 05/05/2025
|
SI-BONE, Inc. Reports Financial Results for the First Quarter 2025 and Updates 2025 Guidance
- First Quarter 2025 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $47.3 million, representing growth of 24.9% U.S. revenue of $44.8 million, representing growth of 26.6% Gross margin of 79.7%, representing an improvement of 80 basis points Net loss of $6.5 million, representing an improvement of 40.0% Positive adjusted EBITDA of $0.5 million $144.4 million in cash and equivalents, with net cash usage in the quarter declining 31.7% to $5.6 million Recent Operational Highlights (any comparisons are to the prior year period) Over 1,400 active U.S. physicians with 300 physicians added in the quarter, representing 27.3% growth CMS FY 2026 proposed hospital inpatient rule for New Technology Add-On Payment (“NTAP”) effective October 1, 2025, paying an additional amount up to $3,960 for procedures involving iFuse TORQ TNT SANTA CLARA, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today reported financial results for the quarter ended March 31, 2025.
- 05/05/2025
|
SI-BONE, Inc. (SIBN) Q4 2024 Earnings Call Transcript
- SI-BONE, Inc. (SIBN) Q4 2024 Earnings Call Transcript
- 02/24/2025
|
Si-Bone (SIBN) Reports Q4 Loss, Tops Revenue Estimates
- Si-Bone (SIBN) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.27 per share a year ago.
- 02/24/2025
|
SI-BONE, Inc. Reports Record Financial Results for the Fourth Quarter 2024 and Issues 2025 Guidance
- Achieves 26% worldwide revenue growth and positive adjusted EBITDA in Fourth Quarter 2024 Achieves 26% worldwide revenue growth and positive adjusted EBITDA in Fourth Quarter 2024
- 02/24/2025
|
Bruker Appoints Laura Francis to its Board of Directors
- BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (Nasdaq: SIBN), a medical device company s.
- 02/21/2025
|
Si-Bone (SIBN) Expected to Beat Earnings Estimates: Should You Buy?
- Si-Bone (SIBN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 02/17/2025
|
SI-BONE to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 24, 2025
- SANTA CLARA, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the fourth quarter and full year ended December 31, 2024 after market close on Monday, February 24, 2025. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
- 02/03/2025
|
Wall Street Analysts Believe Si-Bone (SIBN) Could Rally 64.71%: Here's is How to Trade
- The average of price targets set by Wall Street analysts indicates a potential upside of 64.7% in Si-Bone (SIBN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 12/12/2024
|
Wall Street Analysts See an 83.56% Upside in Si-Bone (SIBN): Can the Stock Really Move This High?
- The consensus price target hints at an 83.6% upside potential for Si-Bone (SIBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 11/26/2024
|
SI-BONE To Present at Piper Sandler 36th Annual Healthcare Conference on December 4, 2024
- SANTA CLARA, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Piper Sandler Healthcare Conference in New York. Management will be hosting a fireside chat on Wednesday, December 4, 2024, at 11:00 a.m. Eastern Time / 8:00 a.m. Pacific Time.
- 11/20/2024
|
SI-BONE, Inc. (SIBN) Q3 2024 Earnings Call Transcript
- SI-BONE, Inc. (NASDAQ:SIBN ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Saqib Iqbal - Senior Director of Investor Relations Laura Francis - Chief Executive Officer Anshul Maheshwari - Chief Financial Officer Conference Call Participants Craig Bijou - BofA Securities Young Li - Jefferies Drew Ranieri - Morgan Stanley Caitlin Cronin - Canaccord Richard Newitter - Truist Securities Operator Good afternoon, and welcome to SI-BONE's Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
- 11/12/2024
|
Si-Bone (SIBN) Reports Q3 Loss, Lags Revenue Estimates
- Si-Bone (SIBN) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.25 per share a year ago.
- 11/12/2024
|
SI-BONE, Inc. Reports Financial Results for the Third Quarter 2024 and Updates Guidance
- SANTA CLARA, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving sacropelvic disorders, today reported financial results for the quarter ended September 30, 2024.
- 11/12/2024
|
SI-BONE Receives Transitional Pass-Through Payment Status for iFuse Bedrock Granite™
- The iFuse Bedrock Granite™ system is a Breakthrough Device Designation technology that provides pelvic fixation and sacroiliac joint fusion, in conjunction with lumbar spinal fusion procedures The iFuse Bedrock Granite™ system is a Breakthrough Device Designation technology that provides pelvic fixation and sacroiliac joint fusion, in conjunction with lumbar spinal fusion procedures
- 11/05/2024
|
Strength Seen in Si-Bone (SIBN): Can Its 6.9% Jump Turn into More Strength?
- Si-Bone (SIBN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- 10/30/2024
|
SI-BONE To Report Third Quarter 2024 Financial Results on November 12, 2024
- SANTA CLARA, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the third quarter of 2024 after market close on Tuesday, November 12, 2024. Management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
- 10/22/2024
|
SIBN Stock Up After First-In-Patient Use of FDA Breakthrough Device
- SI-BONE aims to address the unmet clinical needs of complex pelvic fragility fractures by providing a solution that improves both surgical efficiency and patient recovery.
- 10/14/2024
|
SI-BONE, Inc. Announces First-In-Patient Procedures with FDA Breakthrough Device for Pelvic Fracture Fixation
- SANTA CLARA, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to providing surgical solutions for sacropelvic disorders, today announced first-in-patient procedures with the FDA-designated breakthrough device, iFuse TORQ TNT™ Implant System (TNT). Designed to address the anatomic and biomechanical challenges of pelvic fragility fractures, particularly in patients with poor bone quality, TNT offers a significant advancement over traditional cannulated screws.
- 10/10/2024
|
Wall Street Analysts Think Si-Bone (SIBN) Could Surge 40.3%: Read This Before Placing a Bet
- The average of price targets set by Wall Street analysts indicates a potential upside of 40.3% in Si-Bone (SIBN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 08/26/2024
|
SI-BONE (SIBN) Receives FDA Nod for Its TNT Implant System
- SI-BONE (SIBN) receives FDA 510(k) clearance for its iFuse TORQ TNT implant system, followed by a Breakthrough Device Designation award by the FDA.
- 08/26/2024
|
SI-BONE To Present at Morgan Stanley 22nd Annual Global Healthcare Conference on September 4, 2024
- SANTA CLARA, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference in New York. Management will be hosting a fireside chat on Wednesday, September 4, 2024, at 10:45 a.m. Eastern Time / 7:45 a.m. Pacific Time.
- 08/22/2024
|
SI-BONE, Inc. Receives 510(k) Clearance and FDA Breakthrough Device Designation for Pelvic Fracture Fixation System
- SANTA CLARA, Calif., Aug. 20, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to providing surgical solutions for sacropelvic disorders, announces FDA 510(k) clearance of the iFuse TORQ TNT™ Implant System (TNT). The TNT implant system is designed to meet the specific anatomical and bone mineral density needs of the sacrum and ilium and will serve as the next generation technology for pelvic fragility fracture fixation and sacroiliac joint fusion.
- 08/20/2024
|
Wall Street Analysts Believe Si-Bone (SIBN) Could Rally 64.45%: Here's is How to Trade
- The consensus price target hints at a 64.5% upside potential for Si-Bone (SIBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 08/08/2024
|
SI-BONE To Present at Canaccord Genuity 44th Annual Growth Conference on August 14, 2024
- SANTA CLARA, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will be participating in the upcoming 2024 Canaccord Genuity 44th Annual Growth Conference in Boston. Management will be hosting a fireside chat on Wednesday, August 14th, 2024, at 3:30 p.m. Eastern Time/ 1:30 p.m. Pacific Time.
- 08/06/2024
|
SI-BONE, Inc. (SIBN) Q2 2024 Earnings Call Transcript
- SI-BONE, Inc. (NASDAQ:SIBN ) Q2 2024 Earnings Conference Call August 5, 2024 4:30 PM ET Company Participants Saqib Iqbal - Senior Director of Investor Relations Laura Francis - Chief Executive Officer Anshul Maheshwari - Chief Financial Officer Conference Call Participants Matthew O'Brien - Piper Sandler Andrew Ranieri - Morgan Stanley Xuyang Li - Jefferies Caitlin Cronin - Canaccord Genuity David Turkaly - Citizens JMP Ross Osborn - Cantor Fitzgerald Operator Good afternoon and welcome to SI-BONE's Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
- 08/05/2024
|
Si-Bone (SIBN) Reports Q2 Loss, Tops Revenue Estimates
- Si-Bone (SIBN) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.30 per share a year ago.
- 08/05/2024
|
SI-BONE, Inc. Reports Financial Results for the Second Quarter 2024
- Increases 2024 revenue guidance to $165 million - $167 millionExpects to achieve positive Adjusted EBITDA in Fourth Quarter 2024
- 08/05/2024
|
7 Leading MedTech Stocks for Next-Gen Health Solutions
- While technology lately has been framed in the context of computer hardware or software, it can also apply to the broader field of medicine. Therefore, investors should consider the viable field of MedTech stocks.
- 07/31/2024
|
SI-BONE To Report Second Quarter 2024 Financial Results on August 5, 2024
- SANTA CLARA, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the second quarter of 2024 after market close on Monday, August 5, 2024. Management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
- 07/15/2024
|
SI-BONE To Present at Truist Securities 2024 MedTech Conference on June 18, 2024
- SANTA CLARA, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming 2024 Truist Securities MedTech Conference in Boston. Management will be hosting a fireside chat on Tuesday, June 18, at 3:40 p.m. Eastern Time / 12:40 p.m. Pacific Time.
- 06/05/2024
|
SI-BONE Expands Portfolio with the Launch of New Offering for the iFuse Bedrock Granite Implant System and Completes Inaugural Surgical Procedures
- SANTA CLARA, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced the first cases completed with the smaller, 9.5 mm diameter, iFuse Bedrock Granite® Implant (Granite 9.5). When placed across the SI joint, the Granite implant provides sacroiliac fusion and spinopelvic fixation as a foundational element for multi-segment spinal fusion.
- 05/07/2024
|
SI-BONE, Inc. (SIBN) Q1 2024 Earnings Call Transcript
- SI-BONE, Inc. (NASDAQ:SIBN ) Q1 2024 Results Conference Call May 6, 2024 4:30 PM ET Company Participants Saqib Iqbal - Senior Director, Investor Relations Laura Francis - Chief Executive Officer Anshul Maheshwari - Chief Financial Officer Conference Call Participants Craig Bijou - Bank of America Securities Matthew O'Brien - Piper Sandler Drew Ranieri - Morgan Stanley Dave Turkaly - Citizen JMP Caitlin Cronin - Canaccord Genuity David Saxon - Needham & Company Sam Brodovsky - Truist Securities Ross Osborn - Cantor Fitzgerald Operator Good afternoon and welcome to SI-Bone First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
- 05/06/2024
|
Si-Bone (SIBN) Reports Q1 Loss, Tops Revenue Estimates
- Si-Bone (SIBN) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.32 per share a year ago.
- 05/06/2024
|
SI-BONE, Inc. Reports Financial Results for the First Quarter 2024
- Annual guidance increased to $164 million - $166 million, implying annual growth of ~18% - 20% Annual guidance increased to $164 million - $166 million, implying annual growth of ~18% - 20%
- 05/06/2024
|
Si-Bone (SIBN) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
- Si-Bone (SIBN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/29/2024
|
SI-BONE To Present at BofA Securities 2024 Healthcare Conference on May 14, 2024
- SANTA CLARA, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming 2024 BofA Securities Healthcare Conference in Las Vegas. Management will be hosting a fireside chat on Tuesday, May 14, at 2:20 p.m. Eastern Time / 11:20 a.m. Pacific Time.
- 04/29/2024
|
SI-BONE To Report First Quarter 2024 Financial Results on May 6, 2024
- SANTA CLARA, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy today announced it will report financial results for the first quarter of 2024 after market close on Monday, May 6, 2024. Management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
- 04/15/2024
|
SI-BONE to Present at Barclays 26th Annual Global Healthcare Conference on March 12, 2024
- SANTA CLARA, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming Barclays 26th Annual Global Healthcare Conference in Miami. Management will be hosting a fireside chat on Tuesday, March 12, at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time.
- 03/04/2024
|
SI-BONE, Inc. Reports Record Fourth Quarter and Full Year 2023 Financial Results and Issues 2024 Guidance
- SANTA CLARA, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the fourth quarter and full year ended December 31, 2023.
- 02/26/2024
|
Si-Bone (SIBN) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
- Si-Bone (SIBN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 02/19/2024
|
SI-BONE To Report Fourth-Quarter and Full-Year 2023 Financial Results on February 26, 2024
- SANTA CLARA, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the fourth quarter and full year ended December 31, 2023 after market close on Monday, February 26, 2024. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
- 02/05/2024
|
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
- Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
- 01/31/2024
|
SI-BONE, Inc. Receives FDA 510(k) Clearance for a Smaller Diameter iFuse Bedrock Granite Implant with an Expanded Indication and Application
- SANTA CLARA, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announces FDA 510(k) premarket clearance of the iFuse Bedrock Granite® Implant System (Granite) in a smaller (9.5 mm) diameter with both an expanded indication in pediatric patients and an expanded application that includes use in the S1 trajectory. When placed across the SI joint, the Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for multi-segment spinal fusion.
- 01/30/2024
|
SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2023
- Fiscal Year 2023 revenue of $138.5 - $138.7 million representing growth of over 30% Fiscal Year 2023 revenue of $138.5 - $138.7 million representing growth of over 30%
- 01/08/2024
|
Si-Bone (SIBN) Crossed Above the 50-Day Moving Average: What That Means for Investors
- Si-Bone (SIBN) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, SIBN broke out above the 50-day moving average, suggesting a short-term bullish trend.
- 11/30/2023
|
Sizing Up SI-BONE After Q3 Earnings
- Today, we take a look at SI-BONE, Inc., a medical device company focused on developing implantable devices for musculoskeletal disorders. The company is targeting a large potential market, delivers consistent sales growth, and has a solid balance sheet. However, SI-BONE is some years away from profitability and the shares have seen some considerable insider selling in 2023.
- 11/16/2023
|
SI-BONE To Present at Piper Sandler 35th Annual Healthcare Conference on November 28, 2023
- SANTA CLARA, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming Piper Sandler Healthcare Conference in New York. Management will be hosting a fireside chat on Tuesday, November 28, 2023, at 3:30 p.m. Eastern Time / 12:30 p.m. Pacific Time.
- 11/14/2023
|
SI-BONE, Inc. (SIBN) Q3 2023 Earnings Call Transcript
- SI-BONE, Inc. (NASDAQ:SIBN ) Q3 2023 Earnings Conference Call November 6, 2023 4:30 PM ET Company Participants Saqib Iqbal - Senior Director of IR Laura Francis - CEO Anshul Maheshwari - CFO Conference Call Participants Young Li - Jefferies Drew Ranieri - Morgan Stanley Craig Bijou - Bank of America David Saxon - Needham & Company Dave Turkaly - JMP Securities Caitlin Cronin - Canaccord Samuel Brodovsky - Truist Securities Operator Good afternoon and welcome to SI-BONE's Third Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode.
- 11/06/2023
|
SI-BONE, Inc. Reports Record Financial Results for the Third Quarter 2023 and Raises Annual Guidance
- Annual guidance increased to $136 million - $137 million, implying annual growth of 28%-29% Annual guidance increased to $136 million - $137 million, implying annual growth of 28%-29%
- 11/06/2023
|
SI-BONE To Present at Jefferies London Healthcare Conference on November 15, 2023
- SANTA CLARA, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming Jefferies London Healthcare Conference in London, UK. Management will be hosting a fireside chat on Wednesday, November 15, 2023, at 4:00 a.m. Eastern Time / 1:00 a.m. Pacific Time.
- 11/01/2023
|
SI-BONE to Report Third Quarter 2023 Financial Results on November 6, 2023
- SANTA CLARA, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the third quarter of 2023 after market close on Monday, November 6, 2023. Management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
- 10/16/2023
|
Si-Bone (SIBN) Upgraded to Buy: Here's Why
- Si-Bone (SIBN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 10/09/2023
|
Has SiBone (SIBN) Outpaced Other Medical Stocks This Year?
- Here is how Si-Bone (SIBN) and Alpine Immune Sciences, Inc. (ALPN) have performed compared to their sector so far this year.
- 09/08/2023
|
SI-BONE: Another Record Quarter, Reinvesting For Future Growth, Reiterate Buy
- SI-BONE, Inc. presents compelling long-term value with robust growth in unit economics, high gross profits, and attractive valuation upside. Q2 FY'23 showed record-breaking sales of $33.3 million, with 31% growth in the U.S. market and 5th consecutive quarter of record revenues. The company's capital allocation and recycling strategies, along with positive sentiment and valuation, support a buy rating.
- 08/31/2023
|
SI-BONE To Present at Morgan Stanley 21st Annual Global Healthcare Conference on September 12, 2023
- SANTA CLARA, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming Morgan Stanley 21st Annual Global Healthcare Conference in New York. Management will be hosting a fireside chat on Tuesday, September 12, 2023, at 9:30 a.m. Eastern Time / 6:30 a.m. Pacific Time.
- 08/29/2023
|
SI-BONE, Inc. (SIBN) Q2 2023 Earnings Call Transcript
- SI-BONE, Inc. (NASDAQ:SIBN ) Q2 2023 Earnings Conference Call August 7, 2023 4:30 PM ET Company Participants Saqib Iqbal - Senior Director, FP&A and Investor Relations Laura Francis - Chief Executive Officer Anshul Maheshwari - Chief Financial Officer Conference Call Participants Craig Bijou - Bank of America Young Li - Jeffries Kyle Rose - Canaccord Samuel Brodovsky - Truist Securities Andrew Ranieri - Morgan Stanley Operator Good afternoon, and welcome to SI-BONE's Second Quarter Earnings Conference Call. At this time, all participants are in listen-only mode.
- 08/07/2023
|
SI-BONE to Present at Canaccord Genuity 43rd Annual Growth Conference on August 9, 2023
- SANTA CLARA, Calif., July 19, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming 2023 Canaccord Genuity 43rd Annual Growth Conference in Boston. Management will be hosting a fireside chat on Wednesday, August 9th, 2023, at 12:00 p.m. Eastern Time / 9:00 a.m. Pacific Time.
- 07/19/2023
|
SI-BONE To Report Second Quarter 2023 Financial Results on August 7, 2023
- SANTA CLARA, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the second quarter of 2023 after market close on Monday, August 7, 2023. Management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
- 07/15/2023
|
Best Momentum Stocks to Buy for July 6th
- NCR, GBX and SIBN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 6, 2023.
- 07/06/2023
|
New Strong Buy Stocks for July 6th
- GBX, GFF, AVDX, NCR and SIBN have been added to the Zacks Rank #1 (Strong Buy) List on July 6, 2023.
- 07/06/2023
|
SI-BONE: Rating Higher On Fundamental, Economic Grounds
- SI-BONE is pushing higher in revenues and gross profit, clipping another strong quarter. It pulled in 80% gross margin and expects this on a revised FY'23 outlook. Additional fundamental catalysts are the revised Granite segment outlook and increase in surgeon engagement.
- 06/15/2023
|
SI-BONE To Present at Jefferies 2023 Healthcare Conference on June 7, 2023
- SANTA CLARA, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming 2023 Jefferies Healthcare Conference in New York. Management will be hosting a fireside chat on Wednesday, June 7th, 2023, at 9:00 a.m. Eastern Time / 6:00 a.m. Pacific Time.
- 05/24/2023
|
Why Shares of Si-Bone Jumped Tuesday
- Si-Bone makes the iFuse Implant System for the sacroiliac joint, found in the lower back. The company said it increased its surgeon base to 950 surgeons in the U.S. Revenue for Si-Bone was up 46% year over year.
- 05/02/2023
|
SI-BONE, Inc. (SIBN) Q1 2023 Earnings Call Transcript
- SI-BONE, Inc. (NASDAQ:SIBN ) Q1 2023 Earnings Conference Call May 1, 2023 4:30 PM ET Company Participants Marissa Bych - IR, Gilmartin Group Laura Francis - Chief Executive Officer Anshul Maheshwari - Chief Financial Officer Conference Call Participants Craig Bijou - Bank of America Drew Ranieri - Morgan Stanley Young Li - Jefferies Sam Brodovsky - Truist Dave Turkaly - JMP Securities Kyle Rose - Canaccord Ross Osborn - Cantor Fitzgerald David Saxon - Needham & Company Operator Good afternoon, and welcome to SI-BONE's First Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode.
- 05/01/2023
|
Si-Bone (SIBN) Reports Q1 Loss, Tops Revenue Estimates
- Si-Bone (SIBN) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.52 per share a year ago.
- 05/01/2023
|
SI-BONE to Present at Bank of America Merrill Lynch 2023 Global Healthcare Conference
- SANTA CLARA, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming 2023 Bank of America Merrill Lynch Global Healthcare Conference in Las Vegas. Management will be hosting a fireside chat on Tuesday, May 9th, 2023, at 1:55 p.m. Eastern Time / 10:55 a.m. Pacific Time.
- 04/24/2023
|
SI-BONE To Report First Quarter 2023 Financial Results on May 1, 2023
- SANTA CLARA, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the first quarter of 2023 after market close on Monday, May 1, 2023. Management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
- 04/10/2023
|
SI-BONE, Inc. (SIBN) Q4 2022 Earnings Call Transcript
- SI-BONE, Inc. (NASDAQ:SIBN ) Q4 2022 Earnings Conference Call February 27, 2023 4:30 PM ET Company Participants Saqib Iqbal - Director of Investor Relations Laura Francis - Chief Executive Officer Anshul Maheshwari - Chief Financial Officer Conference Call Participants Kyle Rose - Canaccord David Rescott - Truist Securities Craig Bijou - Bank of America Ross Osborn - Cantor Fitzgerald Dave Turkaly - JMP Securities Drew Ranieri - Morgan Stanley David Saxon - Needham & Company Operator Good afternoon, and welcome to SI-BONE's Fourth Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode.
- 02/27/2023
|
Si-Bone (SIBN) Reports Q4 Loss, Tops Revenue Estimates
- Si-Bone (SIBN) delivered earnings and revenue surprises of 23.81% and 0.48%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 02/27/2023
|
SI-BONE To Report Fourth Quarter 2022 Financial Results on February 27, 2023
- SANTA CLARA, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the fourth quarter of 2022 after market close on Monday, February 27, 2023. Management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
- 02/06/2023
|
SI-BONE: Multiple Inflection Points On The Horizon In FY 2023
- SI-BONE, Inc. presents as a niche operator in the surgical intervention of sacroiliac disorders. There are multiple inflection points on the horizon for SI-BONE in FY 2023.
- 12/30/2022
|
SI-BONE, Inc. (SIBN) CEO Laura Francis on Q3 2022 Results - Earnings Call Transcript
- SI-BONE, Inc. (NASDAQ:SIBN ) Q3 2022 Earnings Conference Call November 7, 2022 4:30 PM ET Company Participants Marissa Bych - IR, Gilmartin Group Laura Francis - Chief Executive Officer Anshul Maheshwari - Chief Financial Officer Conference Call Participants Kyle Rose - Canaccord Craig Bijou - Bank of America David Rescott - Truist Securities Andrew Ranieri - Morgan Stanley David Turkaly - JMP Securities Ross Osborn - Cantor Fitzgerald Young Li - Jefferies David Saxon - Needham & Company Operator Good afternoon, and welcome to SI-BONE's Third Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode.
- 11/07/2022
|
Si-Bone (SIBN) Reports Q3 Loss, Tops Revenue Estimates
- Si-Bone (SIBN) delivered earnings and revenue surprises of 8.89% and 0.29%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/07/2022
|
SI-BONE To Report Third Quarter 2022 Financial Results on November 7, 2022
- SANTA CLARA, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the third quarter of 2022 after market close on Monday, November 7, 2022. Management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
- 10/17/2022
|
SI-BONE To Present at The Morgan Stanley 20th Annual Global Healthcare Conference
- SANTA CLARA, Calif., Aug. 23, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming Morgan Stanley 20th Annual Global Healthcare Conference. Management will be hosting a fireside chat presentation on Wednesday, September 14th, 2022, at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time.
- 08/23/2022
|
SI-BONE, Inc. (SIBN) CEO Laura Francis on Q2 2022 Results - Earnings Call Transcript
- SI-BONE, Inc. (NASDAQ:SIBN ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Matt Bacso - IR, Gilmartin Group Laura Francis - Chief Executive Officer Anshul Maheshwari - Chief Financial Officer Conference Call Participants David Saxon - Needham & Company Craig Bijou - Bank of America David Rescott - Truist Securities Andrew Ranieri - Morgan Stanley David Turkaly - JMP Securities Operator Good afternoon, and welcome to SI-BONE's Second Quarter Earnings Conference Call. At this time, all participants are in listen-only mode.
- 08/08/2022
|
Si-Bone (SIBN) Reports Q2 Loss, Tops Revenue Estimates
- Si-Bone (SIBN) delivered earnings and revenue surprises of -10.20% and 1.85%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/08/2022
|
Analysts Estimate Si-Bone (SIBN) to Report a Decline in Earnings: What to Look Out for
- Si-Bone (SIBN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 08/01/2022
|
SI-BONE, Inc.'s (SIBN) CEO Laura Francis on Q1 2022 Results - Earnings Call Transcript
- SI-BONE, Inc. (NASDAQ:SIBN ) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Matt Basco - IR, Gilmartin Group Laura Francis - Chief Executive Officer Anshul Maheshwari - Chief Financial Officer Conference Call Participants Craig Bijou - Bank of America Drew Ranieri - Morgan Stanley Gibran Ahmed - Canaccord David Rescott - Truist Securities David Saxon - Needham Ross Osborn - Cantor Fitzgerald Operator Good afternoon and welcome to SI-BONE's First Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode.
- 05/09/2022
|
Si-Bone (SIBN) Reports Q1 Loss, Tops Revenue Estimates
- Si-Bone (SIBN) delivered earnings and revenue surprises of -20.93% and 0.31%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/09/2022
|
Earnings Preview: Si-Bone (SIBN) Q1 Earnings Expected to Decline
- Si-Bone (SIBN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 05/02/2022
|
SI-BONE To Present at BofA Securities 2022 Healthcare Conference
- SANTA CLARA, Calif., April 18, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming 2022 Bank of America Healthcare Conference in Las Vegas. Management will be hosting a fireside chat presentation on Wednesday, May 11th, 2022, at 12:40 p.m. Pacific Time / 3:40 p.m. Eastern Time.
- 04/18/2022
|
SI-BONE, Inc. (SIBN) CEO Laura Francis On Q4 2021 Results - Earnings Call Transcript
- SI-BONE, Inc. (SIBN) CEO Laura Francis On Q4 2021 Results - Earnings Call Transcript
- 02/28/2022
|
SI-BONE's (SIBN) CEO Laura Francis on Q3 2021 Results - Earnings Call Transcript
- SI-BONE's (SIBN) CEO Laura Francis on Q3 2021 Results - Earnings Call Transcript
- 11/08/2021
|
Si-Bone (SIBN) Reports Q3 Loss, Lags Revenue Estimates
- Si-Bone (SIBN) delivered earnings and revenue surprises of -17.07% and -1.87%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 11/08/2021
|
SI-BONE To Report Third Quarter 2021 Financial Results on November 8, 2021
- SANTA CLARA, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the third quarter of 2021 after market close on Monday, November 8, 2021. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
- 10/18/2021
|
SI-BONE, Inc. Announces UnitedHealthcare Adopts Exclusive iFuse Only Coverage for Minimally Invasive SI Joint Fusion
- The transition to an exclusive triangular implant policy by UnitedHealthcare, the nation's largest health insurer, is supported by over 100+ peer-reviewed publications, and comes as SI-BONE surpasses 60,000 iFuse procedures performed by more than 2,500 surgeons worldwide The transition to an exclusive triangular implant policy by UnitedHealthcare, the nation's largest health insurer, is supported by over 100+ peer-reviewed publications, and comes as SI-BONE surpasses 60,000 iFuse procedures performed by more than 2,500 surgeons worldwide
- 10/11/2021
|
SI-BONE to Participate in Upcoming Conferences
- SANTA CLARA, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that it will be participating in the following upcoming investor conferences:
- 08/23/2021
|
SI-BONE Q2 Sales Beat Estimates But Higher Costs Hit Profitability, Maintains FY21 Revenue Outlook
- SI-BONE Inc (NASDAQ: SIBN) reported Q2 sales of $22.2 million, beating the consensus of $21.96 million, representing a 58% Y/Y increase over the COVID-19 impacted 2020 period. U.S. revenue of $20.2 million increased 53% Y/Y.
- 08/03/2021
|
SI-BONE, Inc. (SIBN) CEO Laura Francis on Q2 2021 Results - Earnings Call Transcript
- SI-BONE, Inc. (SIBN) CEO Laura Francis on Q2 2021 Results - Earnings Call Transcript
- 08/02/2021
|
Si-Bone (SIBN) Reports Q2 Loss, Tops Revenue Estimates
- Si-Bone (SIBN) delivered earnings and revenue surprises of -7.69% and 0.77%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/02/2021
|
SI-BONE: Q2 Earnings Insights
- Shares of SI-BONE (NASDAQ:SIBN) were flat in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 4.55% over the past year to ($0.42), which missed the estimate of ($0.39).
- 08/02/2021
|
SI-BONE, Inc. Reports Second Quarter 2021 Financial Results and Announces Exclusive Coverage from Anthem
- Record Second Quarter 2021 Worldwide Revenue of $22.2 million Record Second Quarter 2021 Worldwide Revenue of $22.2 million
- 08/02/2021
|
SI-BONE, Inc. Announces Anthem, Inc. Adopts Coverage Guidelines for Sacroiliac Joint Fusion Exclusive to the Triangular iFuse Implant System® for Its More Than 40 Million Members
- Anthem is America's 2nd largest commercial health insurer and joins more than 35 other health plans to offer coverage exclusively for the triangular iFuse Implant System Anthem is America's 2nd largest commercial health insurer and joins more than 35 other health plans to offer coverage exclusively for the triangular iFuse Implant System
- 08/02/2021
|
SI-BONE To Report Second Quarter 2021 Financial Results on August 2, 2021
- SANTA CLARA, Calif., July 20, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the second quarter of 2021 after market close on Monday, August 2, 2021. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
- 07/20/2021
|
SI-BONE, Inc. Announces Centene Establishes Positive Coverage for MIS SI Joint Fusion including the Triangular iFuse Implant System
- New positive coverage policy provides access to iFuse as an important treatment option for patients with chronic sacroiliac joint pain and dysfunction New positive coverage policy provides access to iFuse as an important treatment option for patients with chronic sacroiliac joint pain and dysfunction
- 07/14/2021
|
SI-BONE's Sacroiliac Joint Implant Show Accelerated Fusion, Reduction In Opioid Use
- SI-BONE Inc (NASDAQ: SIBN) has announced the publication of 2-year results from the SALLY study of the iFuse-3D Implant System. Clinical results at 24 months showed marked and sustained improvements in the sacroiliac (SI) joint pain, patient function, and quality of life.
- 07/08/2021
|
SI-BONE, Inc. Announces Publication of iFuse-3D Implant Clinical Study Results Showing Accelerated Fusion, Immediate and Sustained Clinical Improvements and Reduction in Opioid Use
- There are now 95 peer-reviewed publications demonstrating the safety, effectiveness, biomechanical or economic benefits of iFuse Technology™ There are now 95 peer-reviewed publications demonstrating the safety, effectiveness, biomechanical or economic benefits of iFuse Technology™
- 07/07/2021
|
SI-BONE, Inc. Announces the Introduction of the SI-BONE SImulator™ Powered by Medability for iFuse Surgeon Training and Education
- SANTA CLARA, Calif., July 02, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced the worldwide launch of the SI-BONE SImulator™.
- 07/02/2021
|
French National Healthcare System Adopts Exclusive Reimbursement Policy for SI-BONE, Inc.'s iFuse-3D Implant System™
- Exclusive Coverage Takes Effect June 1, 2021, and Extends for 5 Years Exclusive Coverage Takes Effect June 1, 2021, and Extends for 5 Years
- 06/15/2021
|
SI-BONE to Present at the 2021 JMP Securities Life Sciences Conference
- SANTA CLARA, Calif., June 08, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming 2021 JMP Securities Life Sciences Conference. Management is scheduled to present on Thursday, June 17 at 2:30 p.m. Eastern Time / 11:30 a.m. Pacific Time.
- 06/08/2021
|
SI-BONE, Inc. (SIBN) CEO Laura Francis on Q1 2021 Results - Earnings Call Transcript
- SI-BONE, Inc. (SIBN) CEO Laura Francis on Q1 2021 Results - Earnings Call Transcript
- 05/03/2021
|
Si-Bone (SIBN) Reports Q1 Loss, Tops Revenue Estimates
- Si-Bone (SIBN) delivered earnings and revenue surprises of 2.63% and 7.14%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 05/03/2021
|
Recap: SI-BONE Q1 Earnings
- Shares of SI-BONE (NASDAQ:SIBN) remained quited after the company reported Q1 results. Quarterly Results Earnings per share were up 21.28% year over year to ($0.37), which beat the estimate of ($0.39).
- 05/03/2021
|
SI-BONE, Inc. Reports First Quarter 2021 Financial Results and Reiterates 2021 Financial Guidance
- SANTA CLARA, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended March 31, 2021.
- 05/03/2021
|
SI-BONE Appoints Anshul Maheshwari as Chief Financial Officer and Announces the Addition of Helen Loh and Laura Francis to the Board of Directors
- SANTA CLARA, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced the appointment of Anshul Maheshwari as the company's Chief Financial Officer effective April 20, 2021, and the addition of Helen Loh and Laura Francis to its Board of Directors effective April 18, 2021. The appointment of Mr. Maheshwari completes the recently announced senior leadership transition which includes Laura Francis succeeding Jeff Dunn as Chief Executive Officer, and Tony Recupero becoming President, Commercial Operations. Jeff Dunn will remain with the company as Executive Chairman.
- 04/19/2021
|
SI-BONE To Report First Quarter 2021 Financial Results on May 3, 2021
- SANTA CLARA, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the first quarter of 2021 after market close on Monday, May 3, 2021. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
- 04/15/2021
|
SI-BONE, Inc. (SIBN) CEO Jeff Dunn on Q4 2020 Results - Earnings Call Transcript
- SI-BONE, Inc. (SIBN) CEO Jeff Dunn on Q4 2020 Results - Earnings Call Transcript
- 03/08/2021
|
Si-Bone (SIBN) Reports Q4 Loss, Tops Revenue Estimates
- Si-Bone (SIBN) delivered earnings and revenue surprises of 6.67% and 0.43%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 03/08/2021
|
Recap: SI-BONE Q4 Earnings
- Shares of SI-BONE (NASDAQ:SIBN) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 22.22% year over year to ($0.28), which beat the estimate of ($0.30).
- 03/08/2021
|
SI-BONE, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Issues 2021 Financial Guidance
- SANTA CLARA, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter and full year ended December 31, 2020.
- 03/08/2021
|
Earnings Outlook For SI-BONE
- SI-BONE (NASDAQ:SIBN) releases its next round of earnings this Monday, March 08. Get the latest predictions in Benzinga's essential guide to the company's Q4 earnings report.
- 03/05/2021
|
SI-BONE, Inc. Announces that Priority Health Became the 36th Payor with Exclusive iFuse Coverage Policy
- Updated Blue Cross Blue Shield Association Evidence Rating Supports only Triangular Implants Updated Blue Cross Blue Shield Association Evidence Rating Supports only Triangular Implants
- 12/21/2020
|
SI-BONE to Present at the 23rd Annual Needham Growth Conference and the 39th Annual J.P. Morgan Healthcare Conference
- SANTA CLARA, Calif., Dec. 17, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced today that the company will be participating in the upcoming 23rd Annual Needham Growth Conference and the 39th Annual J.P. Morgan Healthcare Conference.
- 12/17/2020
|
SI-BONE, Inc. Announces that Humana Establishes Exclusive Coverage for iFuse in MIS SI Joint Fusion Procedures
- Humana is one of the 5 largest commercial payors in the U.S. and joins 36 other commercial health plans that offer coverage for the triangular iFuse Implant System only Humana is one of the 5 largest commercial payors in the U.S. and joins 36 other commercial health plans that offer coverage for the triangular iFuse Implant System only
- 12/16/2020
|
SI-BONE, Inc. (SIBN) CEO Jeff Dunn on Q3 2020 Results - Earnings Call Transcript
- SI-BONE, Inc. (SIBN) CEO Jeff Dunn on Q3 2020 Results - Earnings Call Transcript
- 11/02/2020
|
SI-BONE, Inc. Reports Third Quarter 2020 Financial Results and 2020 Revenue Guidance
- SANTA CLARA, Calif. , Nov. 02, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended September 30, 2020.
- 11/02/2020
|
